Adaptive Biotechnologies, a high-flying startup that makes technology to read the human immune system, has officially filed to go public and seeks to raise $230 million from investors.
Founded in 2009 by brothers Chad and Harlan Robins, Adaptive Biotechnologies is a leader among a crop of Seattle-based biotech ventures. The 346-person company previously raised more than $400 million to develop its immunosequencing technology.
